Lysophosphatidic Acid Receptor 3 CT (EDG-7)Catalogue number: X1227B
|Product Type||Blocking Peptide|
|Application||Antibody function blocking|
Endothelial Cell Differentiation Gene-7 (EDG7) (LPA3) belongs to a family of G-protein coupled receptors whose ligands are lysophospholipids. The ligand for EDG-7 is lysophospholipid. There are 8 known members of the EDG receptor family and they are implicated in mediating growth related effects such as induction of cellular proliferation, alterations in differentiation and survival and suppression of apoptosis. They also evoke cellular effector functions that are dependent on cytoskeletal responses such as contraction, secretion, adhesion and chemotaxis. EDG receptors are developmentally regulated and differ in tissue distribution. They couple to multiple types of G proteins to signal through ras and MAP kinase, rho, phospholipase C and several protein tyrosine kinases. EDG7 (LPA3) is expressed in prostate as well as other tissues.
Synonyms: Blocking peptide for use in Western blotting with Anti-EDG7 (LPA3) (CT) (Cat. No. X1183P)
Product Form: Unconjugated
Formulation: Provided in solution at 1 mg/ml in phosphate buffered saline.
Concentration: See vial for concentration
For use with EDG7 (LPA3) (CT) polyclonal antibody (Cat. No. X1183P).
Functional Analysis: Western Blotting
Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles
Product Stability: Products are stable for one year from purchase when stored properly
Shipping Conditions: Ship at ambient temperature, freeze upon arrival
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
Lysophosphatidic Acid Receptor 3 CT (EDG-7)